Inpatient prescribing trends and differences in drug acquisition costs of long-acting injectable subcutaneous risperidone versus paliperidone palmitate: A single-center medication use evaluation

Introduction Literature comparing differences in efficacy of inpatient initiation of long-acting paliperidone palmitate once monthly (PP1M) and subcutaneous risperidone long acting-injectable (SC-RLAI) is currently limited and inconclusive. Differences in drug costs may guide choice of the preferred...

Cijeli opis

Spremljeno u:

Bibliografski detalji
Glavni autori:	Andrew Chantha Hean, PharmD, BCPS, BCPP, Cadence Wong, Jung Hoon Park, PharmD, BCPS, BCCCP, Craig Stevens, PharmD, BCPS, Casey Tiefenthaler, PharmD, BCPP
Format:	Artigo
Jezik:	Inglês
Izdano:	American Association of Psychiatric Pharmacists 2026-02-01
Serija:	Mental Health Clinician
Teme:	risperidone paliperidone long-acting injectable drug cost inpatient
Online pristup:	https://theijpt.org/doi/pdf/10.9740/mhc.2026.02.007
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Inpatient prescribing trends and differences in drug acquisition costs of long-acting injectable subcutaneous risperidone versus paliperidone palmitate: A single-center medication use evaluation

Slični predmeti